Gene therapy for cisplatin-induced ototoxicity: A systematic review of in vitro and experimental animal studies

Otology and Neurotology

Volumn 33, Issue 3, 2012, Pages 302-310

  Waissbluth, Sofia ^a   Pitaro, Jacob ^b   Daniel, Sam J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Cisplatin; Deafness; Ector; Gene therapy; Ototoxicity; Plasmid

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CISPLATIN; NERVE GROWTH FACTOR; OTOS PROTEIN, HUMAN; PROTEIN; SMALL INTERFERING RNA;

ANIMAL; CBA MOUSE; CHEMICALLY INDUCED DISORDER; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETICS; HEARING DISORDER; HUMAN; META ANALYSIS; MOUSE; OXIDATIVE STRESS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CISPLATIN; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HEARING DISORDERS; HUMANS; MICE; MICE, INBRED CBA; NERVE GROWTH FACTORS; OXIDATIVE STRESS; PROTEINS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84861096328     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e318248ee66     Document Type: Review

References (107)

1. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003;4:889-901. (Pubitemid 36722480)
2. Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 2007;15: 364-9. (Pubitemid 47373985)
3. Howell SB, Safaei R. CTR1 as a determinant of platinum drug transport. In: Bonetti ALR, Muggia F, Howell, SB, eds. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. New York, NY: Humana Press; 2009:89-94.
4. More SS, Akil O, Ianculescu AG, et al. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 2010; 30:9500-9.
5. Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010;176:1169-80.
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-20. (Pubitemid 41130944)
7. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-98.
8. Rybak LP, Husain K, Evenson L, et al. Protection by 4- methylthiobenzoic acid against cisplatin-induced ototoxicity: antioxidant system. Pharmacol Toxicol 1997;81:173-9. (Pubitemid 27432572)
9. Gabaizadeh R, Staecker H, Liu W, et al. BDNF protection of auditory neurons from cisplatin involves changes in intracellular levels of both reactive oxygen species and glutathione. Brain Res Mol Brain Res15 1997;50:71-8. (Pubitemid 27488891)
10. So H, Kim H, Lee JH, et al. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol 2007;8:338-55. (Pubitemid 47222431)
11. Devarajan P, Savoca M, Castaneda MP, et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res 2002;174:45-54. (Pubitemid 35305031)
12. Rybak LP, Whitworth CA, Mukherjea D, et al. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226: 157-67. (Pubitemid 46428033)
13. Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2001;22:113-42. (Pubitemid 32674345)
14. Giacca M. Introduction to gene therapy. In: Giacca M, ed. Gene Therapy. New York, NY: Springer-Verlag Italia; 2010:1-7.
15. Pfannenstiel S, Praetorius M. Protection and regeneration of sensory epithelia of the inner ear. HNO 2008;56:13-20.
16. Staecker H. Herpes simplex viral vector gene-based therapy to prevent loss of auditory sensory cells from stress-induced apoptosis. In: David J, Lim JS, ed. Cell and Molecular Biology of the Ear. New York, NY: Kluwer Academic/Plenum; 2000:239-57
17. Mukherjea D, Jajoo S, Sheehan K, et al. NOX3 NADPH oxidase couples transient receptor potential vanilloid 1 to signal transducer and activator of transcription 1Ymediated inflammation and hearing loss. Antioxid Redox Signal 2011;14:999-1010.
18. Neve RL, Lim F. Overview of gene delivery into cells using HSV- 1Ybased vectors. Curr Protoc Neurosci 1999;4:1-7.
19. Lalwani AK, Mhatre AN. Cochlear gene therapy. Ear Hear 2003;24:342-8. (Pubitemid 37022146)
20. Van de Water TR, Staecker H, Halterman MW, et al. Gene therapy in the inner ear. Mechanisms and clinical implications. Ann N Y Acad Sci 1999;884:345-60.
21. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004;3:318-29. (Pubitemid 38499759)
22. Bartlett DW, Davis ME. 705. A practical approach to siRNAbased treatment design using bioluminescent imaging and mathematical modeling. Mol Ther. 2006;13:S272-3.
23. Kalinec GM, Webster P, Lim DJ, et al. A cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol Neurootol 2003;8:177-89. (Pubitemid 36736926)
24. Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 1981;23:175-82. (Pubitemid 11173621)
25. Rivolta MN, Holley MC. Cell lines in inner ear research. J Neurobiol 2002;53:306-18. (Pubitemid 35252683)
26. Bowers WJ, Chen X, Guo H, et al. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther 2002;6:12-8. (Pubitemid 36124265)
27. Chen XW, Li H, Cao KL, et al. The transduction of neurotrophin- 3/GDNF attenuates the SGNC damage in deaf mice. Zhonghua Yi Xue Za Zhi 2003;83:1517-20.
28. Chan DK, Lieberman DM, Musatov S, et al. Protection against cisplatin-induced ototoxicity by adeno-associated virus-mediated delivery of the X-linked inhibitor of apoptosis protein is not dependent on caspase inhibition. Otol Neurotol 2007;28:417-25. (Pubitemid 46607920)
29. Cooper LB, Chan DK, Roediger FC, et al. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol Neurotol 2006;27:484-90.
30. Mukherjea D, Jajoo S, Whitworth C, et al. Short interfering RNA against transient receptor potential vanilloid 1 attenuates cisplatininduced hearing loss in the rat. J Neurosci 2008;28:13056-65.
31. Siomi H, Siomi MC. On the road to reading the RNA-interference code. Nature 2009;457:396-404.
32. Chen X, Frisina RD, Bowers WJ, et al. HSV amplicon-mediated neurotrophin-3 expression protects murine spiral ganglion neurons from cisplatin-induced damage. Mol Ther 2001;3:958-63. (Pubitemid 32611305)
33. Staecker H, Liu W, Malgrange B, et al. Vector-mediated delivery of bcl-2 prevents degeneration of auditory hair cells and neurons after injury. ORL J Otorhinolaryngol Relat Spec 2007;69:43-50. (Pubitemid 46005773)
34. Wang GP, Xie J, Liu YP, et al. Adenovirus-mediated delivery of bcl-2 gene attenuates cisplatin-induced degeneration of cultured spiral ganglion cells. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009;44:930-4.
35. Kim HJ, Lee JH, Kim SJ, et al. Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 2010;30:3933-46.
36. Mukherjea D, Jajoo S, Kaur T, et al. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid Redox Signal 2010;13:589-98.
37. Ta LE, Bieber AJ, Carlton SM, et al. Transient receptor potential vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010;6:15.
38. Puntambekar P, Mukherjea D, Jajoo S, et al. Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression. J Neurochem 2005;95:1689-703. (Pubitemid 41804065)
39. Cioffi DL. The skinny on TRPV1. Circ Res 2007;100:934-6. (Pubitemid 46598915)
40. Mattson MP, Chan SL. Calcium orchestrates apoptosis. Nat Cell Biol 2003;5:1041-3. (Pubitemid 37509106)
41. Liang F, Schulte BA, Qu C, et al. Inhibition of the calcium- and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. Neuroscience 2005;135:263-71. (Pubitemid 41219754)
42. Agopyan N, Head J, Yu S, et al. TRPV1 receptors mediate particulate matter-induced apoptosis. Am J Physiol Lung Cell Mol Physiol 2004;286:L563-72. (Pubitemid 38233628)
43. Howell SB, Safaei R, Larson CA, et al. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 2010;77:887-94.
44. Shirazi FH, Molepo JM, Stewart DJ, et al. Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells. Toxicol Appl Pharmacol 1996;140: 211-8. (Pubitemid 26366843)
45. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 1993;67:1171-6. (Pubitemid 23172848)
46. So H, Kim H, Kim Y, et al. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1. J Assoc Res Otolaryngol 2008;9:290-306.
47. So HS, Kim HJ, Lee JH, et al. Flunarizine induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection of auditory cells from cisplatin. Cell Death Differ 2006;13:1763-75.
48. Sahin K, Tuzcu M, Sahin N, et al. Nrf2/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene. Food Chem Toxicol 2010;48:2670-4.
49. Kim HJ, So HS, Lee JH, et al. Heme oxygenase-1 attenuates the cisplatin-induced apoptosis of auditory cells via down-regulation of reactive oxygen species generation. Free Radic Biol Med 2006;40:1810-9.
50. Delprat B, Boulanger A, Wang J, et al. Downregulation of otospiralin, a novel inner ear protein, causes hair cell degeneration and deafness. J Neurosci 2002;22:1718-25. (Pubitemid 35386290)
51. Zhuo XL, Wang Y, Zhuo WL, et al. Adenoviral-mediated upregulation of Otos, a novel specific cochlear gene, decreases cisplatin- induced apoptosis of cultured spiral ligament fibrocytes via MAPK/mitochondrial pathway. Toxicology 2008;248:33-8.
52. Rybak LP, Mukherjea D, Jajoo S, et al. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 2009;219:177-86.
53. Duan M, Venail F, Spencer N, et al. Treatment of peripheral sensorineural hearing loss: gene therapy. Gene Ther 2004;11: S51-6. (Pubitemid 39359447)
54. Ryan AF, Mullen LM, Doherty JK. Cellular targeting for cochlear gene therapy. Adv Otorhinolaryngol 2009;66:99-115.
55. van Ruijven MW, de Groot JC, Klis SF, et al. The cochlear targets of cisplatin: an electrophysiological and morphological timesequence study. Hear Res 2005;205:241-8. (Pubitemid 40813286)
56. Izumikawa M, Minoda R, Kawamoto K, et al. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 2005;11:271-6. (Pubitemid 40460554)
57. Kawamoto K, Sha SH, Minoda R, et al. Antioxidant gene therapy can protect hearing and hair cells from ototoxicity. Mol Ther 2004;9:173-81. (Pubitemid 38256543)
58. Staecker H, Kopke R, Malgrange B, et al. NT-3 and/or BDNF therapy prevents loss of auditory neurons following loss of hair cells. Neuroreport 1996;7:889-94. (Pubitemid 26167971)
59. Oshima K, Shimamura M, Mizuno S, et al. Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats. FASEB J 2004; 18:212-4.
60. Maeda Y, Fukushima K, Nishizaki K, et al. In vitro and in vivo suppression of GJB2 expression by RNA interference. Hum Mol Genet 2005;14:1641-50. (Pubitemid 40895516)
61. Liu YH, Ke XM, Qin Y, et al. Adeno-associated virus-mediated Bcl-xL prevents aminoglycoside-induced hearing loss in mice. Chin Med J 2007;120:1236-40. (Pubitemid 47232907)
62. Shi L, Dong MM, Shi WJ, et al. Construction of bicistronic eukaryotic vector containing basic fibroblast growth factor and study of their functions in gene therapy for hearing impairment. Zhonghua Er Bi Yan Hou Ke Za Zhi 2003;38:21-3.
63. Deng Z, Wang J, Qiu J, et al. Protection of NT3 gene transfection on the guinea pig cochlea treated with gentamicin. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004;18:231-3.
64. Chen Q, Guo WW, Wu Y, et al. Adenovirus-mediated NT3 gene transfer protects spiral ganglion neurons from degeneration after noise trauma. Sheng Li Xue Bao 2002;54:263-6.
65. Liu Y, Okada T, Shimazaki K, et al. Protection against aminoglycoside- induced ototoxicity by regulated AAV vectorYmediated GDNF gene transfer into the cochlea. Mol Ther 2008;16: 474-80. (Pubitemid 351314985)
66. Yagi M, Kanzaki S, Kawamoto K, et al. Spiral ganglion neurons are protected from degeneration by GDNF gene therapy. J Assoc Res Otolaryngol 2000;1:315-25. (Pubitemid 32410196)
67. Wang J, Tymczyszyn N, Yu Z, et al. Overexpression of X-linked inhibitor of apoptosis protein protects against noise-induced hearing loss in mice. Gene Ther 2011;18:560-8.
68. Kawamoto K, Yagi M, Stover T, et al. Hearing and hair cells are protected by adenoviral gene therapy with TGF-beta1 and GDNF. Mol Ther 2003;7:484-92. (Pubitemid 36553417)
69. Pfannenstiel SC, Praetorius M, Plinkert PK, et al. Bcl-2 gene therapy prevents aminoglycoside-induced degeneration of auditory and vestibular hair cells. Audiol Neurootol 2009;14:254-66.
70. Maisonpierre PC, Le Beau MM, Espinosa R 3rd, et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991;10:558-68.
71. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 1995;18:223-53.
72. Ylikoski J, Pirvola U, Moshnyakov M, et al. Expression patterns of neurotrophin and their receptor mRNAs in the rat inner ear. Hear Res 1993;65:69-78. (Pubitemid 23054416)
73. Fritzsch B, Tessarollo L, Coppola E, et al. Neurotrophins in the ear: their roles in sensory neuron survival and fiber guidance. Prog Brain Res 2004;146:265-78. (Pubitemid 37541388)
74. Ockel M, von Schack D, Schropel A, et al. Roles of neurotrophin-3 during early development of the peripheral nervous system. Philos Trans R Soc Lond B Biol Sci 1996;351:383-7. (Pubitemid 126745344)
75. Stankovic K, Rio C, Xia A, et al. Survival of adult spiral ganglion neurons requires erbB receptor signaling in the inner ear. J Neurosci 2004;24:8651-61. (Pubitemid 39362960)
76. Schecterson LC, Bothwell M. Neurotrophin and neurotrophin receptor mRNA expression in developing inner ear. Hear Res 1994;73:92-100. (Pubitemid 24061122)
77. Fritzsch B, Farinas I, Reichardt LF. Lack of neurotrophin 3 causes losses of both classes of spiral ganglion neurons in the cochlea in a region-specific fashion. J Neurosci 1997;17:6213-25. (Pubitemid 27329896)
78. Fritzsch B, Silos-Santiago I, Bianchi LM, et al. The role of neurotrophic factors in regulating the development of inner ear innervation. Trends Neurosci 1997;20:159-64. (Pubitemid 27116287)
79. Schindelhauer D, Schuffenhauer S, Gasser T, et al. The gene coding for glial cell line derived neurotrophic factor (GDNF) maps to chromosome 5p12-p13.1. Genomics 1995;28:605-7.
80. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell lineYderived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-2. (Pubitemid 23186789)
81. Rodrigues DM, Li AY, Nair DG, et al. Glial cell lineYderived neurotrophic factor is a key neurotrophin in the postnatal enteric nervous system. Neurogastroenterol Motil 2011;23:e44-56.
82. Trupp M, Ryden M, Jornvall H, et al. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell Biol 1995;130:137-48.
83. Keithley EM, Ma CL, Ryan AF, et al. GDNF protects the cochlea against noise damage. Neuroreport 1998;9:2183-7. (Pubitemid 28338203)
84. Aarnisalo AA, Pirvola U, Liang XQ, et al. Apoptosis in auditory brainstem neurons after a severe noise trauma of the organ of Corti: intracochlear GDNF treatment reduces the number of apoptotic cells. ORL J Otorhinolaryngol Relat Spec 2000;62:330-4.
85. Alam SA, Ikeda K, Oshima T, et al. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res 2000;141:28-38. (Pubitemid 30125313)
86. Van De Water TR, Lallemend F, Eshraghi AA, et al. Caspases, the enemy within, and their role in oxidative stressYinduced apoptosis of inner ear sensory cells. Otol Neurotol. 2004;25:627-32. (Pubitemid 39079792)
87. Wang P, Song JH, Song DK, et al. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. Cell Signal 2006;18:1528-35. (Pubitemid 43832088)
88. Dean EJ, Ranson M, Blackhall F, et al. X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets 2007;11:1459-71. (Pubitemid 350200481)
89. Kashkar H. X-linked inhibitor of apoptosis: a chemoresistance factor or a hollow promise. Clin Cancer Res 2010;16:4496-502.
90. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 2011;278: 403-13.
91. Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Arch 2005;451:143-50. (Pubitemid 41424917)
92. Toth DM, Szoke E, Bolcskei K, et al. Nociception, neurogenic inflammation and thermoregulation in TRPV1 knockdown transgenic mice. Cell Mol Life Sci 2010;68:2589-601.
93. Rybak LP, Husain K, Morris C, et al. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000;21:513-20. (Pubitemid 30432460)
94. Li W, Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog 2009;48:91-104.
95. Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med 2008;74:1526-39.
96. Slebos DJ, Ryter SW, Choi AM. Heme oxygenase-1 and carbon monoxide in pulmonary medicine. Respir Res 2003;4:7.
97. Lee IT, Luo SF, Lee CW, et al. Overexpression of HO-1 protects against TNF-alpha-mediated airway inflammation by downregulation of TNFR1-dependent oxidative stress. Am J Pathol 2009;175:519-32.
98. Brown DI, Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med. 2009;47:1239-53.
99. Krause KH. Tissue distribution and putative physiological function of NOX family NADPH oxidases. Jpn J Infect Dis 2004; 57:S28-9
100. Martyn KD, Frederick LM, von Loehneysen K, et al. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006;18:69-82 (Pubitemid 41415716)
101. Geiszt M. NADPH oxidases: new kids on the block. Cardiovasc Res 2006;71:289-99
102. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313 (Pubitemid 46209993)
103. Banfi B, Malgrange B, Knisz J, et al. NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem 2004;279:46065-72. (Pubitemid 39491600)
104. Kuo YM, Zhou B, Cosco D, et al. The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci U S A 2001;98:6836-41 (Pubitemid 32538303)
105. Sinani D, Adle DJ, Kim H, et al. Distinct mechanisms for Ctr1- mediated copper and cisplatin transport. J Biol Chem 2007;282: 26775-85 (Pubitemid 47501950)
106. Garcia Berrocal JR, Mendez-Benegassi I, Marti C, et al. Intervention of spiral ligament fibrocytes in the metabolic regulation of the inner ear [in Spanish] Acta Otorrinolaringol Esp 2008;59:494-9
107. Decourt B, Hillman D, Bouleau Y, et al. Is otospiralin inner ear specific? Evidence for its expression in mouse brain. Int J Dev Neurosci 2009;27:87-96.